belantamab mafodotin + nirogacestat + lenalidomide + dexamethasone

This is a **four-drug combination** regimen under investigation for the treatment of **relapsed or refractory multiple myeloma**. The components and their mechanisms are: - **Belantamab mafodotin**: An antibody-drug conjugate targeting B-cell maturation antigen (BCMA) on myeloma cells, delivering a cytotoxic payload (mafodotin, a microtubule inhibitor) directly to the cancer cell to induce apoptosis and immune-mediated toxicity. - **Nirogacestat**: A gamma-secretase inhibitor that increases BCMA levels on the cell surface and reduces soluble BCMA, thereby enhancing anti-BCMA agent activity. This may potentiate the efficacy of belantamab mafodotin. - **Lenalidomide**: An immunomodulatory agent with anti-neoplastic and anti-angiogenic properties, used widely as a backbone therapy in multiple myeloma. - **Dexamethasone**: A corticosteroid that reduces inflammation, exerts direct and indirect anti-myeloma effects, and is standard in myeloma regimens. This combination is being evaluated for potential **synergistic efficacy** and an improved safety profile compared to standard therapies, with particular focus on overcoming resistance and reducing ocular toxicities associated with belantamab mafodotin alone[1][2][5][7].